THE Therapeutic Goods
Administration has listed the new
Genotropin GoQuick delivery
device on the Pharmaceutical
Benefits Scheme effective 01 Aug.
The product is the first
disposable, multi-dose, pre-filled
pen on the market that has been
designed with ‘dose memory’
technology aimed at reducing
dosing error, as well as a needle
cover, whilst Genotropin
[Somatropin (rbe), recombinant
human growth hormone] is a
synthetic version of human growth
hormone for the treatment of
growth hormone deficiency.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.